(Q40852134)

24 September 2017

1 reference

title

Cytokine adjuvants: lessons from the past--guidelines for the future? (English)

1 reference

24 September 2017

Hughes HP

1

1 reference

24 September 2017

1 May 1998

1 reference

Veterinary Immunology and Immunopathology

24 September 2017

1 reference

24 September 2017

63

1 reference

24 September 2017

1-2

1 reference

24 September 2017

131-138

1 reference

Interleukin 2 abrogates the nonresponsive state of T cells expressing a forbidden T cell receptor repertoire and induces autoimmune disease in neonatally thymectomized mice

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2427%2898%2900089-0

7 January 2021

Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2427%2898%2900089-0

7 January 2021

Multiple administration with interleukin-2 potentiates antigen-specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2427%2898%2900089-0

7 January 2021

Regulation of major histocompatibility complex class II expression by Pasteurella haemolytica leukotoxin.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2427%2898%2900089-0

7 January 2021

Three-cell-type clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2427%2898%2900089-0

7 January 2021

Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2427%2898%2900089-0

7 January 2021

Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2427%2898%2900089-0

7 January 2021

Adjuvants, endocrines and conserved epitopes; factors to consider when designing "therapeutic vaccines".

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2427%2898%2900089-0

7 January 2021

Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2427%2898%2900089-0

7 January 2021

10.1016/S0165-2427(98)00089-0

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9656448